Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

Related Posts

Cybin: Researching Psychedelic Therapies for a Variety of Issues Using a Range of Delivery Methods

Cybin files 13th provisional patent application focused on building up its telemedicine capabilities

VIDEO: Cybin (CYBN.NE) Completes 51st Pre-Clinical Psychedelic Molecule Study

VIDEO: Cybin (CYBN.NE) selects SAD and GAD as targets for their CYB004 psychedelic molecule

VIDEO: Cybin (CYBN.NE) files international patent application with Patent Cooperation Treaty (PCT)

VIDEO: Cybin (CYBN.NE) receives approval from IRB for CYB001 Phase II clinical trial

More on CYBN.NE

Cybin: Researching Psychedelic Therapies for a Variety of Issues Using a Range of Delivery Methods

Cybin files 13th provisional patent application focused on building up its telemedicine capabilities

VIDEO: Cybin (CYBN.NE) Completes 51st Pre-Clinical Psychedelic Molecule Study

VIDEO: Cybin (CYBN.NE) selects SAD and GAD as targets for their CYB004 psychedelic molecule

VIDEO: Cybin (CYBN.NE) files international patent application with Patent Cooperation Treaty (PCT)

VIDEO: Cybin (CYBN.NE) receives approval from IRB for CYB001 Phase II clinical trial